An engineered HIV-1 Gag-based VLP displaying high antigen density induces strong antibody-dependent functional immune responses
暂无分享,去创建一个
B. Clotet | S. Marfil | J. Blanco | J. Carrillo | M. L. Rodríguez de la Concepción | L. Cervera | F. Gòdia | Sonia Gutiérrez-Granados | María Mercedes Segura | B. Trinité | C. Aguilar-Gurrieri | V. Urrea | Edwards Pradenas | C. Ávila-Nieto | F. Tarrés-Freixas | A. Pons-Grífols | R. Ortiz | A. Barajas | Carlos Ávila-Nieto | Julià Blanco | Jorge Carrillo | Ferran Tarrés-Freixas | Carmen Aguilar-Gurrieri | María Luisa Rodríguez de la Concepción | Victor Urrea | Benjamin Trinité | Raquel Ortiz | Edwards Pradenas | Pau Blanco | Sílvia Marfil | Luis Manuel Molinos-Albert | Ana Barajas | Anna Pons-Grífols | Ismael Varela | Laura Cervera | Sònia Gutiérrez-Granados | María Mercedes Segura | Francesc Gòdia | L. M. Molinos-Albert | Ismael Varela
[1] D. Montefiori,et al. Homologous and Heterologous Covid-19 Booster Vaccinations , 2022, The New England journal of medicine.
[2] J. Mascola,et al. A multiclade env–gag VLP mRNA vaccine elicits tier-2 HIV-1-neutralizing antibodies and reduces the risk of heterologous SHIV infection in macaques , 2021, Nature Medicine.
[3] J. Klingström,et al. Heterologous ChAdOx1 nCoV-19 and mRNA-1273 Vaccination , 2021, The New England journal of medicine.
[4] P. Kalra,et al. Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine , 2021, The New England journal of medicine.
[5] A. Borobia,et al. Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial , 2021, The Lancet.
[6] L. Cervera,et al. Characterization of HIV‐1 virus‐like particles and determination of Gag stoichiometry for different production platforms , 2021, Biotechnology and bioengineering.
[7] R. Center,et al. Immunogenicity of HIV-1-Based Virus-Like Particles with Increased Incorporation and Stability of Membrane-Bound Env , 2021, Vaccines.
[8] B. He,et al. Parainfluenza Virus 5 Priming Followed by SIV/HIV Virus-Like-Particle Boosting Induces Potent and Durable Immune Responses in Nonhuman Primates , 2021, Frontiers in Immunology.
[9] S. Ferrari,et al. Author contributions , 2021 .
[10] M. Nussenzweig,et al. Antibody Affinity Shapes the Choice between Memory and Germinal Center B Cell Fates , 2020, Cell.
[11] D. Irvine,et al. Multifaceted Effects of Antigen Valency on B Cell Response Composition and Differentiation In Vivo , 2020, Immunity.
[12] P. Moore,et al. Immunogenicity of HIV-1 Vaccines Expressing Chimeric Envelope Glycoproteins on the Surface of Pr55 Gag Virus-Like Particles , 2020, Vaccines.
[13] D. Baker,et al. Enhancing and shaping the immunogenicity of native-like HIV-1 envelope trimers with a two-component protein nanoparticle , 2019, Nature Communications.
[14] J. Blanco,et al. Production of HIV-1-based virus-like particles for vaccination: achievements and limits , 2019, Applied Microbiology and Biotechnology.
[15] Jerome H. Kim,et al. Novel prime-boost vaccine strategies against HIV-1 , 2019, Expert review of vaccines.
[16] D. Irvine,et al. Immunization expands B cells specific to HIV-1 V3 glycan in mice and macaques , 2019, Nature.
[17] C. Sorzano,et al. A Novel MVA-Based HIV Vaccine Candidate (MVA-gp145-GPN) Co-Expressing Clade C Membrane-Bound Trimeric gp145 Env and Gag-Induced Virus-Like Particles (VLPs) Triggered Broad and Multifunctional HIV-1-Specific T Cell and Antibody Responses , 2019, Viruses.
[18] Jason S McLellan,et al. Structure-Based Vaccine Antigen Design. , 2019, Annual review of medicine.
[19] A. Bolhassani,et al. Induction of a robust humoral response using HIV-1 VLPMPER-V3as a novel candidate vaccine in BALB/c mice. , 2019, Current HIV research.
[20] R. Paredes,et al. Guiding the humoral response against HIV-1 toward a MPER adjacent region by immunization with a VLP-formulated antibody-selected envelope variant , 2018, PloS one.
[21] Dong Soo Yun,et al. Enhancing Humoral Responses Against HIV Envelope Trimers via Nanoparticle Delivery with Stabilized Synthetic Liposomes , 2018, Scientific Reports.
[22] A. Chakraborty,et al. The low spike density of HIV may have evolved because of the effects of T helper cell depletion on affinity maturation , 2018, PLoS computational biology.
[23] K. Überla,et al. Intrastructural Help: Harnessing T Helper Cells Induced by Licensed Vaccines for Improvement of HIV Env Antibody Responses to Virus-Like Particle Vaccines , 2018, Journal of Virology.
[24] B. Clotet,et al. Immunologic Insights on the Membrane Proximal External Region: A Major Human Immunodeficiency Virus Type-1 Vaccine Target , 2017, Front. Immunol..
[25] D. Montefiori,et al. Immunogenicity of a novel Clade B HIV-1 vaccine combination: Results of phase 1 randomized placebo controlled trial of an HIV-1 GM-CSF-expressing DNA prime with a modified vaccinia Ankara vaccine boost in healthy HIV-1 uninfected adults , 2017, PloS one.
[26] Daniel W. Kulp,et al. Effects of partially dismantling the CD4 binding site glycan fence of HIV-1 Envelope glycoprotein trimers on neutralizing antibody induction. , 2017, Virology.
[27] R. Wyatt,et al. Dense Array of Spikes on HIV-1 Virion Particles , 2017, Journal of Virology.
[28] P. Zhu,et al. In vivo electroporation in DNA-VLP prime-boost preferentially enhances HIV-1 envelope-specific IgG2a, neutralizing antibody and CD8 T cell responses. , 2017, Vaccine.
[29] Jordi Villà-Freixa,et al. Proteoliposomal formulations of an HIV-1 gp41-based miniprotein elicit a lipid-dependent immunodominant response overlapping the 2F5 binding motif , 2017, Scientific Reports.
[30] Khuloud T. Al-Jamal,et al. Investigating the effect of tumor vascularization on magnetic targeting in vivo using retrospective design of experiment , 2016, Biomaterials.
[31] A. Collins. IgG subclass co‐expression brings harmony to the quartet model of murine IgG function , 2016, Immunology and cell biology.
[32] A. Jungbauer,et al. Purification of HIV-1 gag virus-like particles and separation of other extracellular particles. , 2016, Journal of chromatography. A.
[33] R. Wyatt,et al. High-Density Array of Well-Ordered HIV-1 Spikes on Synthetic Liposomal Nanoparticles Efficiently Activate B Cells. , 2016, Cell reports.
[34] K. Überla,et al. The improved antibody response against HIV-1 after a vaccination based on intrastructural help is complemented by functional CD8+ T cell responses. , 2016, Vaccine.
[35] Joseph G. Jardine,et al. HIV-1 broadly neutralizing antibody precursor B cells revealed by germline-targeting immunogen , 2016, Science.
[36] Darrell J Irvine,et al. Beyond antigens and adjuvants: formulating future vaccines. , 2016, The Journal of clinical investigation.
[37] K. Überla,et al. Enhancing the Quality of Antibodies to HIV-1 Envelope by GagPol-Specific Th Cells , 2015, The Journal of Immunology.
[38] John P. Moore,et al. Presenting native-like HIV-1 envelope trimers on ferritin nanoparticles improves their immunogenicity , 2015, Retrovirology.
[39] H. Liao,et al. Comparable Antigenicity and Immunogenicity of Oligomeric Forms of a Novel, Acute HIV-1 Subtype C gp145 Envelope for Use in Preclinical and Clinical Vaccine Research , 2015, Journal of Virology.
[40] Daniel W. Kulp,et al. Vaccine-Elicited Tier 2 HIV-1 Neutralizing Antibodies Bind to Quaternary Epitopes Involving Glycan-Deficient Patches Proximal to the CD4 Binding Site , 2015, PLoS pathogens.
[41] Dina N. Kovarik,et al. Multimeric Scaffolds Displaying the HIV-1 Envelope MPER Induce MPER-Specific Antibodies and Cross-Neutralizing Antibodies when Co-Immunized with gp160 DNA , 2014, PloS one.
[42] Gregory J. Hardy,et al. HIV-1 antibodies and vaccine antigen selectively interact with lipid domains. , 2014, Biochimica et biophysica acta.
[43] U. Reichl,et al. A flow-through chromatography process for influenza A and B virus purification. , 2014, Journal of virological methods.
[44] B. Clotet,et al. Anti-MPER antibodies with heterogeneous neutralization capacity are detectable in most untreated HIV-1 infected individuals , 2014, Retrovirology.
[45] H. Liao,et al. Induction of HIV-1 Broad Neutralizing Antibodies in 2F5 Knock-in Mice: Selection against Membrane Proximal External Region–Associated Autoreactivity Limits T-Dependent Responses , 2013, The Journal of Immunology.
[46] A. Lux,et al. Of Mice and Men: The Need for Humanized Mouse Models to Study Human IgG Activity in Vivo , 2012, Journal of Clinical Immunology.
[47] B. Haynes,et al. Rescue of HIV-1 Broad Neutralizing Antibody-Expressing B Cells in 2F5 VH × VL Knockin Mice Reveals Multiple Tolerance Controls , 2011, The Journal of Immunology.
[48] B. Clotet,et al. A cell-to-cell HIV transfer assay identifies humoral responses with broad neutralization activity. , 2011, Vaccine.
[49] Eric O Long,et al. Signal transduction during activation and inhibition of natural killer cells. , 2010, Current protocols in immunology.
[50] Pamela J. Bjorkman,et al. Few and Far Between: How HIV May Be Evading Antibody Avidity , 2010, PLoS pathogens.
[51] Jerome H. Kim,et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. , 2009, The New England journal of medicine.
[52] D. Engelman,et al. Molecular dynamics studies of the transmembrane domain of gp41 from HIV-1. , 2009, Biochimica et biophysica acta.
[53] David C Montefiori,et al. Measuring HIV neutralization in a luciferase reporter gene assay. , 2009, Methods in molecular biology.
[54] Marc C. Johnson,et al. Three-dimensional analysis of budding sites and released virus suggests a revised model for HIV-1 morphogenesis. , 2008, Cell host & microbe.
[55] T. Kamala. Hock immunization: a humane alternative to mouse footpad injections. , 2007, Journal of immunological methods.
[56] Xiping Wei,et al. Human Immunodeficiency Virus Type 1 env Clones from Acute and Early Subtype B Infections for Standardized Assessments of Vaccine-Elicited Neutralizing Antibodies , 2005, Journal of Virology.
[57] A. Matsukawa,et al. INNATE IMMUNE RESPONSE IN TH1- AND TH2-DOMINANT MOUSE STRAINS , 2004, Shock.
[58] H. Schwarz,et al. Analysis of Cd44-Containing Lipid Rafts , 1999, The Journal of cell biology.
[59] Wei Chen,et al. Eliciting T cell immunity against poorly immunogenic tumors by immunization with dendritic cell-tumor fusion vaccines. , 1998, Journal of immunology.
[60] M. Neuberger,et al. Affinity dependence of the B cell response to antigen: a threshold, a ceiling, and the importance of off-rate. , 1998, Immunity.
[61] R. Zinkernagel,et al. The influence of antigen organization on B cell responsiveness. , 1993, Science.